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Abstract
Background: p27Kip1 (p27) is an important negative regulator of the cell cycle and a putative tumor suppressor. The 
finding that a spontaneous germline frameshift mutation in Cdkn1b (encoding p27) causes the MENX multiple 
endocrine neoplasia syndrome in the rat provided the first evidence that Cdkn1b is a tumor susceptibility gene for 
endocrine tumors. Noteworthy, germline p27 mutations were also identified in human patients presenting with 
endocrine tumors. At present, it is not clear which features of p27 are crucial for this tissue-specific tumor 
predisposition in both rats and humans. It was shown that the MENX-associated Cdkn1b mutation causes reduced 
expression of the encoded protein, but the molecular mechanisms are unknown. To better understand the role of p27 
in tumor predisposition and to characterize the MENX animal model at the molecular level, a prerequisite for future 
preclinical studies, we set out to assess the functional properties of the MENX-associated p27 mutant protein (named 
p27fs177) in vitro and in vivo.
Results: In vitro, p27fs177 retains some properties of the wild-type p27 (p27wt) protein: it localizes to the nucleus; it 
interacts with cyclin-dependent kinases and, to lower extent, with cyclins. In contrast to p27wt, p27fs177 is highly 
unstable and rapidly degraded in every phase of the cell-cycle, including quiescence. It is in part degraded by Skp2-
dependent proteasomal proteolysis, similarly to p27wt. Photobleaching studies showed reduced motility of p27fs177 
in the nucleus compared to p27wt, suggesting that in this compartment p27fs177 is part of a multi-protein complex, 
likely together with the degradation machinery. Studies of primary rat newborn fibroblasts (RNF) established from 
normal and MENX-affected littermates confirmed the rapid degradation of p27fs177 in vivo which can be rescued by 
Bortezomib (proteasome inhibitor drug). Overexpression of the negative regulators microRNA-221/222 plays no role in 
regulating the amount of p27fs177 in RNFs and rat tissues.
Conclusion: Our findings show that reduced p27 levels, not newly acquired properties, trigger tumor formation in rats, 
similarly to what has been observed in mice. The molecular characteristics of p27fs177 establish MENX as a useful 
preclinical model to evaluate compounds that inhibit p27 degradation for their efficacy against endocrine tumors.
Background
The putative tumor suppressor p27Kip1 (referred to as
p27) controls the progression from G1 to the S phase by
regulating the activity of cyclinE/and cyclinA/Cdk2 com-
plexes [1]. Several external signals regulate the intracellu-
lar level of p27 by either causing its increase (i.e. serum
deprivation, TGFβ, contact inhibition) or its decrease
(serum stimulation, estrogen, PDGF and others), thereby
rendering p27 a central mediator of mitogenic and anti-
mitogenic signals [2]. In addition to its negative role in
cell cycle progression, p27 is involved in cell migration,
neuronal differentiation and apoptosis [3-5]. Through
studies of a mouse strain expressing a p27 protein
impaired in cyclin/Cdk binding it has been demonstrated
that p27 has a pro-oncogenic effect when it cannot bind
to cyclin/Cdk complexes [6].
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The intracellular level of p27 is regulated at the tran-
scriptional, translational and post-translational level
[7,8], but the best known mechanism is ubiquitin-medi-
ated proteasomal degradation. Two main pathways
involved in p27 degradation have been identified. The
first is mediated by the Skp2-dependent SCF (skp-cullin-
f-box) E3 ligase: phosphorylation of p27 by cyclinE/Cdk2
at a conserved threonine (Thr187) creates a binding site
for Skp2, which allows polyubiquitylation and subsequent
proteasomal degradation of p27. This degradation path-
way is active in the nucleus of G1-S and G2 phase cells [3-
5,9]. The second pathway is mediated by the KPC ubiq-
uitin ligase and is responsible for the degradation of p27
in the cytoplasm at the G0-G1 transition [10].
Phosphorylation at specific residues regulates the activ-
ity of p27: phosphorylation at serine (Ser) 10 regulates its
subcellular localization and stability [11,12]. Studies of
p27S10A (serine 10 substituted by alanin) knock-in mice
demonstrated that phosphorylation at Ser10 stabilizes
p27 during quiescence by affecting its ability to bind to
cyclin-CDK complexes [13]. Ser10 phosphorylation also
triggers the export of p27 from the cell nucleus to the
cytoplasm upon mitogenic stimuli, thereby allowing the
protein's degradation by the KPC ubiquitin ligase [14].
Phosphorylation of p27wt at Thr187, as mentioned
above, targets p27 for proteasomal-mediated degradation
[15], while phosphorylation at Thr198 prevents ubiq-
uitin-dependent degradation of free p27 and regulates the
stability of p27 in G0 phase [16].
W e  r ec e n t ly ide n ti fied a  Cdkn1b germline frameshift
mutation as the cause of a recessive multiple endocrine
neoplasia (MEN)-like syndrome (named MENX) in the
rat [17]. Rats affected by this syndrome (homozygous
mutants) share phenotypic features with the p27 -/-
knock-out mice (increase in size, pituitary tumors) but
show additional neuroendocrine tumors (adrenals, thy-
roid, parathyroid). Interestingly, we and others identified
CDKN1B  germline mutations in patients with a MEN
type 1 (MEN1)-like features, thereby establishing a direct
link between p27 alterations and tumor predisposition
also in humans (MEN4; OMIM # 610755) [17-19]. Ger-
mline  CDKN1B mutations are a rare event in patients
with an MEN1-like phenotype (estimated to be around
1.5-2.8% of cases) [18,19], and some studies failed to
identify them [20,21]. So far, five germline CDKN1B
mutations have been reported and the in vitro functional
studies performed on three of them show that these alter-
ations affect the ability of the encoded protein to bind its
usual protein partners (p27P95S variant) or affect its
amount (ATG-7G>C; stop->Q) [19]. Interestingly, the
phenotype of the stop->Q germline mutation can be res-
cued by proteasomal inhibition in vitro [19].
In the MENX model, p27 protein expression is reduced
or absent in the normal tissues of the mutant rats, but it
becomes detectable in some advanced neoplastic lesions
[17]. Therefore, this mutation is not equivalent to a null
allele and it may possess specific biological functions
within this model system. The mechanisms causing
reduced p27 expression in the MENX-affected rats are
currently unknown.
In humans, neuroendocrine tumors are uncommon
neoplasms and therefore comprehensive molecular stud-
ies are difficult to perform and clinical trials are challeng-
ing to set up. In addition, there are few suitable animal
models of neuroendocrine tumors and this has hampered
the development and preclinical testing of novel targeted
therapeutic approaches against these tumors. In this sce-
nario, the MENX model may be of relevance to identify
novel molecular mechanisms in neuroendocrine tumori-
genesis and to perform preclinical therapy-response
studies. An in depth knowledge of the functional conse-
quences of the underlying genetic mutation in Cdkn1b is
a prerequisite to further exploit the MENX animal model
in preclinical studies. Moreover, since germline CDKN1B
mutations have been found in patients, studies of the
molecular phenotype of the rat mutation may broaden
our understanding of the role of p27 in tumor predisposi-
tion in humans as well. Therefore, we set out to charac-
terize the MENX-associated p27 mutant protein in vitro
and in the patients tissues. Our studies extend to the rats
the observation that the amount of functional p27 is cru-
cial for promoting neuroendocrine tumorigenesis, event
that so far had been formally proven only in genetically
engineered mice.
Results
The MENX mutation in Cdkn1b affects p27 stability
The MENX-associated spontaneous p27 mutation is a
tandem duplication of eight nucleotides in exon 2 of
Cdkn1b (c. 520-528dupTTTCAGAC) starting at codon
176 [17]. The mutated mRNA encodes for a predicted
protein 218 amino acid long, containing a p27-unrelated
C-terminal domain and referred to as p27fs177 (Figure
1a). Previously we showed that the amount of p27fs177 in
normal tissues of affected rats (p27 mut/mut) is
extremely low, but it may increase in areas of advanced
tumors [17]. The amount of Cdkn1b mRNA is similar in
mutant and normal rat tissues [17]. To investigate the
functional properties of p27fs177, we generated vectors
that express p27fs177 or wild-type p27 (p27wt) as fusion
proteins with the green fluorescence protein (GFP). We
also generated a protein with a premature stop codon at
aminoacid 177 (named p27G177X) to evaluate the role of
the p27-unrelated C-terminal domain (Figure 1a).
Upon transfection, all fusion proteins were expressed
and their size was consistent with the predicted protein
length (Figure 1a). p27fs177 was expressed at much lower
level then either p27wt or p27G177X. A time-courseMolatore et al. Molecular Cancer 2010, 9:116
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e x p e r i m e n t  s h o w e d  t h a t  t h e r e  i s  n o  t i m e - d e p e n d e n t
accumulation of p27fs177 (Figure 1b). Using immunoflu-
orescence staining, we previously showed that a Myc-
tagged p27fs177 seems to localize to the nucleus upon
transfection of Rat2 cells, which express endogenous
p27wt, [17]. To avoid misinterpretation of the results due
to possible interference of the endogenous p27 protein,
we set out to assess the localization of p27fs177 in expo-
nentially growing or serum-starved p27 knockout mouse
embryonal fibroblasts (MEFs). Twenty-four hours after
Figure 1 The p27fs177 mutant protein is expressed at low level in vitro due to enhanced degradation. (a) Left: Schematic representation of 
the constructs used. Right: Steady-state level of the three transfected p27 proteins: GFP-p27wt, -p27fs177 and -p27G177X. (b) The level of p27fs177 
does not increase with time post-transfection. p27wt and p27fs177 steady-state levels were analyzed at different times after transfection into MCF7 
cells by Western blotting as in A. On the left, p27wt or p27fs177 indicate the transfected proteins. (c) p27fs177 is unstable compared to p27wt. Kinetic 
of degradation of p27wt, p27fs177 and p27G177× proteins determined after transfection into asynchronously growing MCF7 cells and treatment with 
cycloheximide (CHX) for the indicated times. (d) p27fs177 has a half-life of about 1 hr. Transfected MCF7 cells were incubated with CHX for shorter 
time compared to panel C. (e) Live cell imaging of MCF7 cells transfected with p27wt or p27fs177 and treated for the indicated times with CHX con-
firms the rapid degradation of p27fs177. Wt, wild-type; Untr, untransfected; IB, immunoblot; Exo, exougenous; Endo, endogenous; GFP, green fluores-
cent protein; CHX, cycloheximide.Molatore et al. Molecular Cancer 2010, 9:116
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transfection the proteins are located mainly in the
nucleus, regardless of whether the MEF cells are prolifer-
ating or growth-arrested (see Additional File 1).
We then tested whether the MENX mutation affects
p27 steady-state abundance by changing its rate of degra-
dation. The rate of p27 turnover was measured in expo-
nentially growing MCF7 cells using cycloheximide (CHX)
to block new protein synthesis. The endogenous p27 pro-
tein served as control for the treatment's efficacy. p27wt
and p27G177× showed no decrease during this time
course (0 h to 8 h), whereas p27fs177 was barely detect-
able already 2 hr after treatment (Figure 1c). The fast
kinetic of degradation of p27fs177 was confirmed by
shorter incubation with CHX (Figure 1d). Longer CHX
treatments confirmed the higher stability of p27wt and
p27G177× (half-life of ca. 10 hr) (data not shown). Live
cell imaging of MCF7 cells transfected with p27wt or
p27fs177, and treated with CHX 24 hr post-transfection,
confirmed the very fast degradation of the mutant p27
protein (Figure 1e). Throughout this time frame (from 15
min up to 2 hr) p27fs177-associated fluorescence was
detected only in the nucleus, suggesting that the protein
is degraded in this compartment.
To study in more detail the kinetic of degradation of
p27fs177, we transfected the constructs in Figure 1a into
MCF7 cells and selected clones constitutively expressing
the various proteins (Figure 2a). Upon incubation of these
clonal cell lines with CHX, we obtained results similar to
those observed in transiently-transfected MCF7 cells
(Figure 2b).
The truncated p27G177× protein is as stable as p27wt,
suggesting that the p27-unrelated C-terminal domain of
p27fs177 must be responsible for its fast degradation. To
verify this hypothesis, we cloned the tail of p27fs177, in
frame, at the C-terminus of a different protein, namely
CDK2, to generate the CDK2-p27tail cDNA (Figure 2c
and Additional File 2). We then transfected constructs
expressing the wild-type CDK2 or the CDK2-p27tail
cDNAs into MCF7 cells and observed that while exoge-
nous CDK2 is expressed at high level, the CDK2-p27tail
protein cannot be detected by western blotting (Figure
2c). Following immunoprecipitation, we can detect by
western blotting a faint band having a size consistent with
the predicted CDK2-p27tail protein length (Figure 2c).
The lower expression of the CDK2-p27tail protein is not
due to a lower transfection efficiency of the DNA con-
struct, as demonstrated by co-transfection experiments
with a GFP-encoding plasmid (see Additional File 3).
Thus, our results suggest that p27fs177 is degraded very
rapidly due to the p27-unrelated C-terminal domain.
Interestingly, this domain, when located at the C-termi-
nus, promotes the rapid degradation of an independent
protein (i.e. CDK2).
Turnover of the p27fs177 protein is independent of the cell 
cycle phase
It has been shown that the stability of p27 is dependent
on the cell cycle phase [13]. To verify whether this applies
to p27fs177 we determined the rate of its turnover in G1-
phase and S-phase Clone 9 cells stably-expressing
p27fs177 (Figure 2a). As p27fs177 was undetectable upon
serum deprivation (G0-phase), these results were not
included. The kinetic of degradation of p27fs177 is simi-
lar in both G1 and S phases of the cell cycle (Figure 2d).
Similar results were also observed for p27fs177-Clone 14
(not shown).
Proteasome-mediated degradation of p27fs177 in vitro
p27fs177 is rapidly degraded in every phase of the cell
cycle. p27wt is normally degraded through ubiquitin-
dependent proteasomal degradation. To verify whether
the proteasome mediates p27fs177 degradation, stably
transfected p27fs177-Clone 9 cells were incubated with
CHX in the presence or absence of the proteasome inhib-
itor Epoxomycin (EPOX). Epoxomycin partially inhibits
the degradation of p27fs177, although the protein level is
not completely restored back to that of untreated cells
(Figure 2e). Similar results were obtained using a chemi-
cally distinct proteasome inhibitor, MG132 (not shown).
p27fs177 is unstable due to its C-terminal domain and
is degraded through the proteasome. This could occur
because this protein is recognized as misfolded by the
proteasome or could occur through the canonical ubiq-
uitin-dependent pathways that mediate the degradation
of wild-type p27. This is an important issue to clarify if
we want to exploit this animal model to evaluate in vivo
compounds aimed at restoring p27 function in the tumor
cells by interfering with its degradation. As mentioned
above, p27 is degraded in the nucleus by Skp2_SCF E3-
mediated ubiquitination followed by proteasomal degra-
dation. To determine whether Skp2 is involved in the
turnover of p27fs177, we transfected the above con-
structs into exponentially growing MCF7 cells and
reduced Skp2 expression by siRNA-mediated knock-
down (Figure 3a). Reduction of Skp2, as confirmed by
western blotting (Figure 3b), led to an increase in the lev-
els of both p27wt and p27fs177, whereas transfection of
scrambled siRNA did not increase p27wt levels, attesting
to the specificity of the Skp2-siRNA (Figure 3c). Similar
results were obtained using a pool of different siRNA oli-
gos against Skp2 (Additional File 4). Therefore, p27fs177
is still a substrate of ubiquitination by the Skp2-SCF com-
plex despite the absence of the Thr187 residue. This is an
interesting observation, as it has been amply reported
that phosphorylation at Thr187 creates the recognition
site for Skp2 binding.
If polyubiquitination is a pre-requisite for proteosomal
turnover, then inhibition of the ubiquitination pathwayMolatore et al. Molecular Cancer 2010, 9:116
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should stabilize p27fs177. We tested this hypothesis using
a ubiquitin mutant (UbR7) that inhibits ubiquitin chain
elongation, allowing only monoubiquitination [22].
Cotransfection of this mutant ubiquitin increased the
steady-state abundance of p27wt (control) but not that of
p27fs177 (Figure 3d). This data suggests that polyubiquit-
ination is required for p27wt but not for p27fs177 degra-
dation, although we cannot rule out the possibility that
these proteins are differentially sensitive to conjugation
with UbR7.
In summary, the degradation of p27fs177 is, at least in
part, mediated by the ubiquitin ligase Skp2. However, the
relative differences between p27wt and p27fs177 protein
levels remained under conditions of Skp2 knock-down,
indicating that p27fs177 is degraded also by Skp2-inde-
pendent mechanisms. We speculate that p27fs177 is
directly degraded by the proteasome due to its altered
conformation.
Figure 2 p27fs177 is degraded very fast also in cells stably-transfected with the GFP fusion constructs. (a) Clones stably expressing the various 
p27 mutants. (b) CHX treatment for clones stably expressing p27wt, p27fs177 and p27G177X. Only the exogenous p27 proteins are shown. (c) The 
p27-unrelated, C-terminal domain of p27fs177 is responsible for the rapid degradation of the protein. The CDK2 expression vectors shown on the right 
were transfected into MCF7 cells and protein extracts were immunoprecipitated (IP) overnight with anti-GFP antibody. (d) p27fs177 is very rapidly 
degraded independently from the cell cycle phase. p27fs177 turn-over determination in G1-phase (G1), and S-phase (S) in Clone 9 cells. (e) p27fs177 
is in part degraded through the proteasome. Proliferating p27fs177-Clone 9 cells were treated with CHX and epoxomycin (EPOX, +) or DMSO (-) for 
the indicated times. Untr, untransfected; IB, immunoblot; IP, immunoprecipitation; EPOX, epoxomycin.Molatore et al. Molecular Cancer 2010, 9:116
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The p27fs177 protein is not phosphorylated on Ser10 but 
retains the ability to interact with Cdk2 and Cdk4
Studies of p27S10A knock-in mice (where Ser10 is substi-
tuted by alanine) demonstrated that phosphorylation of
p27 on Ser10 normally stabilizes the protein in quies-
cence by decreasing its ability to bind to cyclin-CDK
complexes [13]. As p27fs177 is very unstable in G0, we
asked whether this was due to lack of phosphorylation on
Ser10. Hela cells were transfected with the p27wt and
p27fs177, and with the control p27S10A mutant that can-
not be phosphorylated at this residue. While p27wt can
be detected using the anti-phospho-Ser10 antibody, both
p27S10A and p27fs177 cannot be (see Additional File 5a).
As p27fs177 is expressed at low level upon transfection,
we also performed immunoprecipitation with the anti-
phospho-Ser10 antibody to increase the sensitivity of the
method. We observed that only p27wt can bind the phos-
pho-specific antibody (see Additional File 5a). Therefore,
p27fs177 is not phosphorylated at Ser10 or the propor-
tion that is phosphorylated is below detection. Thus, lack
of (or extremely reduced) phosphorylation at Ser10 may
concur in making the p27fs177 protein unstable.
It has been shown that the formation of heterotrimeric
p27-cyclin-Cdk complexes is required for p27 degrada-
tion as mutations that abolish the association with cyclin-
Cdks stabilize p27 [13]. Thus, we next decided to deter-
mine whether p27fs177 retains the ability to interact with
Cyclin-Cdk complexes. Serum-starved and exponentially
growing p27fs177-Clone 9 cells were used for co-immu-
noprecipitation (IP) studies. The binding of p27fs177 to
Cyclin D1, Cyclin E, Cdk2 and Cdk4 was determined by
western blotting. The results show that p27fs177 retains
the ability to interact with all proteins albeit with differ-
ent efficiencies (see Additional File 5b). Due to the low
level of p27fs177 present in the cells, the amount of the
Cdks bound to is accordingly low. p27fs177 binds more
efficiently to Cdk4 then to Cdk2.
Nuclear dynamic of p27fs177 revealed by photobleaching
As the p27fs177 protein is degraded very fast in every
p h a s e  o f  t h e  c e l l  c y c l e  a n d  i t  i s  d e t e c t e d  o n l y  i n  t h e
nucleus, we postulated that p27fs177 in this compart-
ment binds to the degradation machinery. Fluorescence
Recovery After Photobleaching (FRAP) is an optical tech-
nique capable of measuring the two dimensional lateral
diffusion of a fluorescent molecule over time in single
cells and which has been applied to study cell membrane
diffusion and protein binding [23]. We used FRAP to
study the diffusion coefficient of the different GFP-p27
proteins. p27wt showed in the nucleus a diffusion coeffi-
cient (D-value) of 8.8 μm2/sec, while p27G177× showed a
D-value of 10.1 μm2/sec (P = 0.22), whereas p27fs177 had
a much lower diffusion coefficient (3.78 μm2/sec) (P =
0.0012) (Table 1 and Additional File 6). Such difference in
Figure 3 Degradation of p27fs177 occurs through Skp2-depen-
dent pathways. (a) Expression of p27 and α-tubulin (control) were as-
sessed in siRNA-treated and untreated cells. (b) Validation of efficient 
knockdown of Skp2 using different DNA concentrations. Probing the 
membrane with α-tubulin ensured equal protein loading. (c) To verify 
the specificity of the siRNA-mediated knock-down of Skp2, a scram-
bled siRNA oligo was transfected in parallel with p27wt plasmid. siRNA 
for knock-down of KPC1 was included as positive control as this protein 
also degrades p27wt. Probing the membrane with α-tubulin ensured 
equal protein loading. (d) A ubiquitin mutant (pUbr7) co-transfected in 
parallel with the p27wt and p27fs177 expression vectors has no effect 
on p27fs177 degradation.Molatore et al. Molecular Cancer 2010, 9:116
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diffusion behavior was not caused by increased molecular
mass of p27fs177 compared to p27wt (ca. 2.3 kDa) as
FRAP recovery rates due to diffusion are weakly depen-
dent on protein mass [23].
Starting at 24 hr after transfection of p27fs177 in the
various recipient cell lines used, the protein is localized in
the nucleus (Additional File 1). At 18-20 hr a percentage
of cells (ca. 30%) still show some cytoplasmic p27fs177
that has not yet been imported into the nucleus. To deter-
mine whether also in this compartment p27fs177 shows
reduced molecular dynamics, we performed FRAP to
measure the diffusion coefficient of the various p27 pro-
teins in the cytoplasm at 18 hr post-transfection of Rat2
cells. The results show that in this compartment the
motility of p27wt, p27fs177 and p27G177× is similar,
indicating that p27fs177 is not associated to a protein
complex in the cytoplasm (Additional File 6).
Instability of p27fs177 in primary rat cells
We could not detect ectopic p27fs177 in quiescent cells.
To study the degradation of p27fs177 during quiescence
in a more physiological system, we established primary
skin fibroblast cell lines from newborn wild-type
(RNFwt) and mutant (RNFmut) rat littermates. Serum-
starvation (ss) and release experiments showed that wild-
type p27 levels fluctuate throughout the cell cycle, as one
might expect: they were elevated in serum-starved cells,
decreased during G1 (up to 24 h), remained lower in S
and G2 phases (up to 48 h) (Figure 4a). The level of
p27fs177 also oscillated throughout the cell cycle but the
protein could not be detected in serum-starved cells (Fig-
ure 4a). Analysis of cyclin A expression confirmed the
progression of RNFs (both wt and mut) through the cell
cycle (Figure 4a). The level of p27fs177 in quiescent RNF-
mut cells increased by adding MG132, indicating that
proteasomal degradation is active also during this phase
(Figure 4a).
In proliferating RNFs, p27fs177 is degraded within
minutes following treatment with CHX, and if we add
Epoxomycin (EPOX) p27fs177 is stabilized (Figure 4b and
4c). Therefore, the low level of endogenous p27fs177 pro-
tein in RNFs is caused by its rapid degradation mediated,
at least in part, by the proteasome, as seen in vitro. The
mutant p27 protein is even less stable in this more physi-
ological system than in vitro.
In REFmut cells a band migrating slower then p27fs177
can be observed at long exposure times but since it is not
affected by any treatment we performed (Figure 4c) nor is
the product of abnormally-spliced Cdkn1b  transcripts
(data not shown) we consider it p27-unrelated.
In view of possible preclinical therapy-response studies
of MENX, we tested the effect of Bortezomib (Velcade®), a
proteasome inhibitor drug currently used to treat
patients with multiple myeloma and other neoplasias
[24], on the stabilization of p27fs177. We detected an
increase in the level of p27fs177 using a dose of the drug
reported to elicit a biochemical response (10 nM). The
restoration of p27fs177 expression lasted until 48 hr post-
treatment and was evident already at 3 hr, in keeping with
the usual short half-life of this protein. In contrast,
p27wt, which is more stable, increases 24 hr after incuba-
tion with Bortezomib and 48 hr later the wild-type pro-
tein is still present at high level (Figure 5).
In many cell types there is an inverse correlation
between p27 level and cell proliferation. To determine
whether the low expression level of p27fs177 has an effect
on cell cycle progression, RNFs were growth-arrested and
monitored following serum stimulation over a 72-h
period for cell cycle progression by flow cytometry. No
significant difference in cell cycle distribution was
observed by FACS analyses between RNFwt and RNFmut
(Figure 4a). Thus, lack of functional p27 within the
MENX model does not grossly affect cell cycle progres-
sion. This is in agreement with what has been observed in
the normal tissues of MENX rats following immunohis-
tochemical staining with the proliferation antigen Ki67
(Pellegata NS, unpublished observation).
The reduced level of p27fs177 in RNFmut is only in
part explained by proteasome-mediated degradation, as it
is slightly lower than that of p27wt in RNFwt cells also in
presence of Epoxomycin. Recently, it has been reported
that miRNA-221&222 down-regulate p27 at the post-
transcriptional level in cell lines and in primary tumors
[8,25]. Therefore, we checked whether the low amount of
p27fs177 in MENX-affected rat tissues and cells might
also be due to an up-regulation of miRNA-221&222.
Table 1: Diffusion coefficient of the various GFP-p27 fusion proteins in the nucleus.
Construct Nuclear Diffusion
D (mm2/sec) sd (yEr ±)
GFP-p27wt 8.81 2.01
GFP-p27fs177 3.78 0.15
GFP-p27G177X 10.1 0.92Molatore et al. Molecular Cancer 2010, 9:116
http://www.molecular-cancer.com/content/9/1/116
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Analysis of the expression of miRNA-221&222 in RNFwt
and RNFmut cells, as well as in a series of normal and
tumor rat adrenal tissues (organ affected by the MENX
syndrome), showed no significant difference in the
expression of these two miRNAs between samples
expressing wild-type or mutant Cdkn1b (see Additional
File 7). Therefore, a higher expression of miRNA-
221&222 does not play a role in the low level of expres-
sion of p27fs177 in either rat primary cells or rat tissues.
Discussion
We show here that the mutant p27 protein associated
with MENX is very unstable due to the p27-unrelated C-
terminal domain. Its rapid degradation is, at least in part,
mediated by the Skp2-dependent ubiquitination pathway,
just as p27wt. Interestingly, it has been reported that
Skp2-dependent ubiquitination and subsequent degrada-
tion of p27 requires the phosphorylation of Thr187,
which is then recognized and bound by the Skp2 ubiq-
uitin ligase. Since p27fs177 lacks the Thr187 residue but
its degradation is still regulated by Skp2 (as seen in
siRNA knock-down experiments), we have to postulate
that a Skp2-dependent but Thr187-independent mecha-
nism for p27 degradation exists, as it had been previously
hypothesized based on studies of cells (fibroblasts, thy-
mocytes) from p27T187A (Thr substituted by Ala)
Figure 4 p27fs177 is highly unstable also in primary rat fibroblasts. (a) RNF mut cells progress through the cell cycle as RNF wt cells. FACS analysis 
of DNA content. (b) CHX treatment on exponentially growing RNFs. The asterisk indicates a non-specific band. (c) Endogenous p27fs177 is in part 
degraded by the proteasome. RNFs were treated with CHX and epoxomycin (+) or DMSO (-) for the indicated times. Left: Endogenous p27fs177 is so 
unstable that often can be detected only in the presence of proteasome inhibitors such as EPOX. Right: p27fs177 is actively degraded not only in ex-
ponentially growing (Exp) RNF mut cells but also in serum-starved cells (SS) and is stabilized by treatment with EPOX.Molatore et al. Molecular Cancer 2010, 9:116
http://www.molecular-cancer.com/content/9/1/116
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knock-in mice [26]. A mutant ubiquitin that inhibits
ubiquitin chain elongation has no effect on the degrada-
tion of p27fs177, while it rescues wild-type p27 degrada-
tion, indicating that p27fs177 is also degraded by
mechanisms different from those modulating the level of
p27wt. However, what is relevant is that the expression of
p27fs177 can be recovered by proteasome-inhibition.
This finding, combined with the fact that p27fs177
retains the capacity to interact with cyclins and Cdks,
suggests that if the expression of this protein can be res-
cued inhibiting the proteasome, it might resume its anti-
proliferative activity.
The fact that p27fs177 retains the potential to bind to
the usual partners of p27 is highly relevant: if this protein
can be re-expressed in the tumor cells, it might then
resume its inhibitory effect on the cell cycle and therefore
prevent or reverse tumor growth in vivo.
Our observation that in some areas of very advanced
tumors in MENX mutant rats p27fs177 is expressed at a
detectable level might not be in contradiction to this
hypothesis. In fact, re-expression of the protein is
observed in rats whose general health status is irrevers-
ibly compromised by the detrimental effects related to
tumor progression.
The slower nuclear dynamic of p27fs177 is therefore
due to its being part of a multi-protein complex, likely
together with the degradation machinery. This is in
agreement with the finding that the nuclear Skp2 ubiq-
uitin ligase plays a role in p27fs177 degradation.
p27 is frequently down-regulated in human tumors and
in some of them increased proteasomal degradation has
been identified as the cause of the reduced p27 level
[27,28]. Because of these findings, efforts have been made
to identify compounds that interfere with the protein
turnover machinery in order to achieve p27 re-expression
in cancer cells. An example is the novel compound,
Argyrin A, which specifically prevents p27 degradation
and holds great promise as anti-cancer drug [29]. Due to
the characteristics of p27fs177 here described, MENX
rats represent a useful pre-clinical model in which to test
the efficacy of targeted therapeutic approaches aiming at
inhibiting p27 degradation. Interestingly, an established
anticancer proteasome inhibitor compound, Bortezomib,
can rescue p27fs177 expression in fibroblasts of MENX-
affected rats. Therefore, MENX might be also employed
to test in vivo the efficacy of Bortezomib against neuroen-
docrine tumors and to study whether the potential effect
of the drug is mediated by reexpression of p27 function.
A Phase II clinical trial aiming at evaluating the effect of
the proteasome inhibitor Bortezomib on metastatic neu-
roendocrine tumors failed to show any objective tumor
response in this patient cohort [30]. However, the
patients had not been stratified for p27 expression, mea-
surement of the increase in p27 expression following
treatment was not among the biological end points of the
study and Bortezomib induces a wide range of off-target
effects [27]. Thus, the efficacy of p27 re-expression in the
treatement of neuroendocrine tumors is still an open
question that can be addressed by studying MENX-
affected rats.
Conclusions
Our findings suggest that the p27fs177 mutant protein
does not acquire novel molecular properties, and triggers
tumor formation in the spontaneous rat MENX model
because it behaves as a hypoactive allele. So far, this had
only been formally proven in various p27 knock-out and
knock-in mouse models [31-33].
The identification of the molecular phenotype of the
few naturally-occurring p27 mutations so far identified in
MENX and in human patients is important to better
understand the link between p27 and neuroendocrine
tumor predisposition (and tumorigenesis in general), and
may provide clues for a targeted management of the fam-
ilies carrying such mutations.
Methods
Plasmid constructs and antibodies
The rat wild-type Cdkn1b cDNA was cloned in the
pEGFP-C3 vector (BD Biosciences, Erembodegem, Bel-
Figure 5 p27fs177 can be stabilized by Bortezomib in primary rat fibroblasts. Exponentially growing RNF wt and RNF mut cells were treated 
with the proteasome inhibitor Bortezomib for the indicated time. The asterisk indicates a non-specific band.Molatore et al. Molecular Cancer 2010, 9:116
http://www.molecular-cancer.com/content/9/1/116
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gium) in frame with the green fluorescent protein (GFP)
tag. A rat Cdkn1b cDNA containing the MENX rat muta-
tion (p27fs177) and a rat Cdkn1b cDNA containing a stop
codon at position 177 (p27G177X) were generated by
PCR.
The rat wild-type Cdkn1b cDNA was cloned in the
pEGFP-C3 vector (BD Biosciences, Erembodegem, Bel-
gium) in frame with the green fluorescent protein (GFP)
tag. A rat Cdkn1b cDNA containing the MENX rat muta-
tion (p27fs177) and a rat Cdkn1b cDNA containing a stop
codon at position 177 (p27G177X) were generated by
PCR.
The pUbr7 construct was gently provided by N. Malek
Primary antibodies used were: anti-p27 monoclonal
antibody (BD Biosciences); anti-Skp2 monoclonal anti-
body; anti-Cyclin A polyconal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). To control for equal
protein loading, α-tubulin immunostaining (Santa Cruz)
was performed.
Cell culture, transfections, protein extraction and Western 
blotting
MCF7 (human breast cancer) cell line was maintained in
RPMI 1640 medium supplemented with 10% fetal bovine
serum, 20 mM L-glutamine, 100 units/ml of penicillin G
sodium, and 100 μg/ml streptomycin. When establishing
stable transfectants, cells were selected by adding 0.4 mg/
ml G418 to the culture medium.
Primary rat fibroblast cells were obtained from the epi-
dermis of newborn rats having a p27 wt/wt (RNF wt) or a
p27fs177/p27fs177 genotype (RNF mut) and were main-
tained in DMEM medium supplemented with 10% fetal
bovine serum, 20 mM L-glutamine, 100 units/ml of peni-
cillin G sodium, 100 μg/ml streptomycin, and Fungizone®
antimycotic (Invitrogen, Darmstadt, Germany).
The cells were grown in a humidified atmosphere con-
taining 5% CO2 a t  3 7 ° C. C e l l s  w e r e  g r o w t h  a r r e s t e d  b y
decreasing the serum concentration in the medium to
0.1% for 72 h and then released by serum addition,
Asynchronously growing cells were transiently trans-
fected with the different constructs when 70-80% conflu-
ent using the FuGene HD reagent (Roche Applied
Bioscience, Basel, Switzerland). Cells were collected and
lysed 24 h later in protein lysis buffer (10 mmol/l Tris-
HCl pH 7·4, 5 mmol/l EDTA, 130 mmol/l NaCl, 1% Tri-
ton, and 1× Mini-Complete protease inhibitors cocktail,
Roche).
Equal protein amounts (50 μg) were resolved on 4-15%
SDS-PAGE pre-cast gels (Invitrogen, Darmstadt, Ger-
many).
Drug treatments and RNA interference
The cells were treated with 25 μg/mL cycloheximide
(Sigma-Aldrich Biochemie, Hamburg, Germany), 10 μM
epoxomycin (Enzo Life Sciences, Lörrach, Germany), or
10 nM Bortezomib (LC Labs, Woburn, MA, USA).
For RNAi studies, short interfering RNA (siRNA)
duplexes specific for Skp2  ( n  =  4 )  ( 1  μ g ;  s i G e n o m e
SMARTpool, Dharmacon, Lafayette, CO, USA) and
KPC1 (1 μg each; ID 133486, 133487 Ambion-Applied
Biosystems, Darmstadt, Germany) were obtained and
transfected into MCF7 cells using X-tremeGENE reagent
(Roche) together with expression plasmids for p27wt (30
ng) or p27fs177 (50 ng). To verify the specificity of the
siRNA-mediated knock-down, a scrambled siRNA oligo
was transfected in parallel.
Immunofluorescence
MCF7 cells were plated on dishes having a cover slip for
microscopy (MatTek Corporation, Ashland, MA, USA)
and transfected as above with p27fs177 and p27wt pro-
tein constructs. To re-create a more physiological condi-
tion (37°C and 5% CO2), dishes were put under a micro-
incubation chamber (Zeiss, Jena, Germany) mounted on
a confocal laser scanning microscope (Zeiss). Images
were taken every 15 min using always the same settings.
Fluorescence activated cell sorting (FACS)
Cells were collected and fixed in 70% ice-cold ethanol and
stored at -20°C until ready to proceed. Cells were rinsed
and resuspended in 1× PBS containing 5 μg/ml propid-
ium iodide and 150 μg/ml RNaseA. After incubation for
30 min at 37°C cells were analyzed in a FACS machine
(Beckman Coulter, Krefeld, Germany) for DNA content.
Immunoprecipitations
500 μg of total protein extracted from the cells were incu-
bated with a polyclonal anti-GFP antibody (BD Biosci-
ences) in IP buffer (5 mM EDTA, 0.5% Triton X-100 in
PBS 1×) and 20 μl of agarose resin overnight at 4°C.
Unbound protein fraction was removed, the resin was
washed five times with IP buffer and immunoprecipitated
proteins were eluted from the agarose resin using Laem-
mli buffer and analyzed by Western blot.
Additional experimental procedures and associated ref-
erence are available in Additional File 8.
Additional material
Additional file 1 Intracellular localization of the p27 fusion proteins. 
p27 -/- mouse embryonic fibroblasts (MEF) exponentially growing (exp) or 
after 72 hrs of serum deprivation (s.s.) were transfected with GFP -p27wt, -
p27fs177 and -p27G177X. Cells were investigated for p27 immunofluores-
cence 24 h after transfection. Cell nuclei were counterstained with 1 μg/ml 
Hoechst before mounting on slides.
Additional file 2 Sequence of the proteins encoded by the constructs 
used for the transient transfections (see Figure 2C). The DNA sequence 
of the CDK2 human gene (NM_001798) was cloned into the pEGFP vector 
in frame with the EGFP gene. By in vitro mutagenesis we changed the stop 
codon of CDK2 from TGA->GGA and then we cloned in frame the 129 bp of 
the p27Fs177 tail, starting at the site of the insertion, in frame with the CDK2 
cDNA. All constructs were confirmed by sequencing.Molatore et al. Molecular Cancer 2010, 9:116
http://www.molecular-cancer.com/content/9/1/116
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